Proteomics and genomics in neuroimmunological disorders

Maire Rose Donnelly, Wojciech Rozek, Pawel S Ciborowski

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Proteomic and genomic technologies, particularly when combined as functional genomics, are promising experimental approaches to creating expression profiles of proteins and their connection to disease specific changes, starting with transcription and ending at the level of posttranslational modifications. It seems that molecular mechanisms underlying many neurodegenerative disorders may have common features. In a short amount of time, proteomics underwent unprecedented development from its early stages of collecting high numbers of protein identifications in a single experiment. Quantitative mass spectrometry of proteins is now a standard approach in all laboratories. However, analytical techniques based on principles of liquid chromatography are dominating and advancing the field. Further technological developments such as single cell analysis, will further facilitate a more precise view of changes occurring in proteomes resulting from alterations in biological systems. Another big step will be to go beyond slowing down or stopping neurodegenerative processes, and push the immune system to repair damage and promote regeneration. To what extent this is possible and how soon it can be accomplished remains an open question. It is certain, however, that understanding functions of complex biological systems, such as duality of neurotoxic/neurothrophic function of mononuclear phagocytes in the brain during inflammation, will require coordinated monitoring of a large number of parameters simultaneously and well-designed proteomic, genomic, and neuro-imaging experiments.

Original languageEnglish (US)
Title of host publicationNeuroimmune Pharmacology
PublisherSpringer International Publishing
Pages941-958
Number of pages18
ISBN (Electronic)9783319440224
ISBN (Print)9783319440200
DOIs
StatePublished - Jan 1 2016

Fingerprint

Genomics
Proteomics
Immune System Phenomena
Single-Cell Analysis
Proteins
Encephalitis
Proteome
Post Translational Protein Processing
Phagocytes
Liquid Chromatography
Neurodegenerative Diseases
Regeneration
Mass Spectrometry
Technology

Keywords

  • 2 dimensional electrophoresis
  • Bioinformatics
  • Biomarker
  • Bottom-up analysis
  • Cerebrospinal fluid
  • Gene arrays
  • Genomics
  • HIV-1 associated dementia
  • Hyphenated techniques
  • Liquid chromatography
  • Mass spectrometry
  • Neurodegeneration
  • Neuroproteomics
  • Protein fingerprinting
  • Proteomics
  • SELDI-TOF
  • SWATH-MS
  • Systems biology
  • Tissue profiling
  • Top-down analysis

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Donnelly, M. R., Rozek, W., & Ciborowski, P. S. (2016). Proteomics and genomics in neuroimmunological disorders. In Neuroimmune Pharmacology (pp. 941-958). Springer International Publishing. https://doi.org/10.1007/978-3-319-44022-4_54

Proteomics and genomics in neuroimmunological disorders. / Donnelly, Maire Rose; Rozek, Wojciech; Ciborowski, Pawel S.

Neuroimmune Pharmacology. Springer International Publishing, 2016. p. 941-958.

Research output: Chapter in Book/Report/Conference proceedingChapter

Donnelly, MR, Rozek, W & Ciborowski, PS 2016, Proteomics and genomics in neuroimmunological disorders. in Neuroimmune Pharmacology. Springer International Publishing, pp. 941-958. https://doi.org/10.1007/978-3-319-44022-4_54
Donnelly MR, Rozek W, Ciborowski PS. Proteomics and genomics in neuroimmunological disorders. In Neuroimmune Pharmacology. Springer International Publishing. 2016. p. 941-958 https://doi.org/10.1007/978-3-319-44022-4_54
Donnelly, Maire Rose ; Rozek, Wojciech ; Ciborowski, Pawel S. / Proteomics and genomics in neuroimmunological disorders. Neuroimmune Pharmacology. Springer International Publishing, 2016. pp. 941-958
@inbook{82116bef9d99454382fd583b03a5cc0f,
title = "Proteomics and genomics in neuroimmunological disorders",
abstract = "Proteomic and genomic technologies, particularly when combined as functional genomics, are promising experimental approaches to creating expression profiles of proteins and their connection to disease specific changes, starting with transcription and ending at the level of posttranslational modifications. It seems that molecular mechanisms underlying many neurodegenerative disorders may have common features. In a short amount of time, proteomics underwent unprecedented development from its early stages of collecting high numbers of protein identifications in a single experiment. Quantitative mass spectrometry of proteins is now a standard approach in all laboratories. However, analytical techniques based on principles of liquid chromatography are dominating and advancing the field. Further technological developments such as single cell analysis, will further facilitate a more precise view of changes occurring in proteomes resulting from alterations in biological systems. Another big step will be to go beyond slowing down or stopping neurodegenerative processes, and push the immune system to repair damage and promote regeneration. To what extent this is possible and how soon it can be accomplished remains an open question. It is certain, however, that understanding functions of complex biological systems, such as duality of neurotoxic/neurothrophic function of mononuclear phagocytes in the brain during inflammation, will require coordinated monitoring of a large number of parameters simultaneously and well-designed proteomic, genomic, and neuro-imaging experiments.",
keywords = "2 dimensional electrophoresis, Bioinformatics, Biomarker, Bottom-up analysis, Cerebrospinal fluid, Gene arrays, Genomics, HIV-1 associated dementia, Hyphenated techniques, Liquid chromatography, Mass spectrometry, Neurodegeneration, Neuroproteomics, Protein fingerprinting, Proteomics, SELDI-TOF, SWATH-MS, Systems biology, Tissue profiling, Top-down analysis",
author = "Donnelly, {Maire Rose} and Wojciech Rozek and Ciborowski, {Pawel S}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-44022-4_54",
language = "English (US)",
isbn = "9783319440200",
pages = "941--958",
booktitle = "Neuroimmune Pharmacology",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Proteomics and genomics in neuroimmunological disorders

AU - Donnelly, Maire Rose

AU - Rozek, Wojciech

AU - Ciborowski, Pawel S

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Proteomic and genomic technologies, particularly when combined as functional genomics, are promising experimental approaches to creating expression profiles of proteins and their connection to disease specific changes, starting with transcription and ending at the level of posttranslational modifications. It seems that molecular mechanisms underlying many neurodegenerative disorders may have common features. In a short amount of time, proteomics underwent unprecedented development from its early stages of collecting high numbers of protein identifications in a single experiment. Quantitative mass spectrometry of proteins is now a standard approach in all laboratories. However, analytical techniques based on principles of liquid chromatography are dominating and advancing the field. Further technological developments such as single cell analysis, will further facilitate a more precise view of changes occurring in proteomes resulting from alterations in biological systems. Another big step will be to go beyond slowing down or stopping neurodegenerative processes, and push the immune system to repair damage and promote regeneration. To what extent this is possible and how soon it can be accomplished remains an open question. It is certain, however, that understanding functions of complex biological systems, such as duality of neurotoxic/neurothrophic function of mononuclear phagocytes in the brain during inflammation, will require coordinated monitoring of a large number of parameters simultaneously and well-designed proteomic, genomic, and neuro-imaging experiments.

AB - Proteomic and genomic technologies, particularly when combined as functional genomics, are promising experimental approaches to creating expression profiles of proteins and their connection to disease specific changes, starting with transcription and ending at the level of posttranslational modifications. It seems that molecular mechanisms underlying many neurodegenerative disorders may have common features. In a short amount of time, proteomics underwent unprecedented development from its early stages of collecting high numbers of protein identifications in a single experiment. Quantitative mass spectrometry of proteins is now a standard approach in all laboratories. However, analytical techniques based on principles of liquid chromatography are dominating and advancing the field. Further technological developments such as single cell analysis, will further facilitate a more precise view of changes occurring in proteomes resulting from alterations in biological systems. Another big step will be to go beyond slowing down or stopping neurodegenerative processes, and push the immune system to repair damage and promote regeneration. To what extent this is possible and how soon it can be accomplished remains an open question. It is certain, however, that understanding functions of complex biological systems, such as duality of neurotoxic/neurothrophic function of mononuclear phagocytes in the brain during inflammation, will require coordinated monitoring of a large number of parameters simultaneously and well-designed proteomic, genomic, and neuro-imaging experiments.

KW - 2 dimensional electrophoresis

KW - Bioinformatics

KW - Biomarker

KW - Bottom-up analysis

KW - Cerebrospinal fluid

KW - Gene arrays

KW - Genomics

KW - HIV-1 associated dementia

KW - Hyphenated techniques

KW - Liquid chromatography

KW - Mass spectrometry

KW - Neurodegeneration

KW - Neuroproteomics

KW - Protein fingerprinting

KW - Proteomics

KW - SELDI-TOF

KW - SWATH-MS

KW - Systems biology

KW - Tissue profiling

KW - Top-down analysis

UR - http://www.scopus.com/inward/record.url?scp=85046005757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046005757&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-44022-4_54

DO - 10.1007/978-3-319-44022-4_54

M3 - Chapter

AN - SCOPUS:85046005757

SN - 9783319440200

SP - 941

EP - 958

BT - Neuroimmune Pharmacology

PB - Springer International Publishing

ER -